marked.bio

anti-PD-1 antibody · antibody

pembrolizumab

126 active trials across 19 of our biomarkers, targeting PD-1. 10 active approvals for a biomarker on marked.bio.

Also known as MK-3475, MK-3475A, lambrolizumab, Keytruda, Keytruda Qlex.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Approvals and pivotal results

Biomarker-selected approvals in the United States and the European Union, with the pivotal trial's results and side effects where we have them. Results from different trials are not directly comparable.

TherapyBiomarkerTumourUnited StatesEuropean Union
pembrolizumab
FDA, 2020
unresectable or metastatic MSI-H or dMMR colorectal cancer (label no longer states line; first approved 2020 for first line) Current label 1.9 has no line restriction. Year confirmed: FDA approval announced 29/06/2020. Source
FDA, 2025
unresectable or metastatic MSI-H or dMMR colorectal cancer, adults FDA approval 19/09/2025; label 1.7. Source
EU (EMA), 2021
first line, metastatic MSI-H or dMMR II/0091, EC decision 21/01/2021. Source
EU (EMA), 2022
unresectable or metastatic MSI-H or dMMR, after fluoropyrimidine-based combination therapy II/0109, EC decision 25/04/2022. EU has no tumour-agnostic MSI-H indication. Source
Keytruda, Keytruda Qlex 		MSI-H / dMMR colorectal Approved 2020 Approved 2021

KEYNOTE-177 vs chemotherapy with or without bevacizumab or cetuximab, 307 randomised
PFS 16.5 months vs 8.2 months, HR 0.60 (0.45-0.80)

Trial details and side effects
Patients
first-line MSI-H or dMMR metastatic colorectal cancer (NCT02563002)
Most common side effects
fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhoea, nausea, rash
Notes
From the FDA approval report; overall survival was immature at approval.
Source
US approval report
pembrolizumab
FDA, 2022
advanced MSI-H or dMMR endometrial carcinoma, progressed after prior systemic therapy in any setting, not candidates for curative surgery/radiation Label 1.17 (single agent). Year confirmed: FDA approval announced 21/03/2022. Source
FDA, 2025
advanced MSI-H or dMMR endometrial carcinoma, progressed after prior systemic therapy, not candidates for curative surgery/radiation FDA approval 19/09/2025; label 1.15 (single agent). Source
EU (EMA), 2022
advanced or recurrent MSI-H or dMMR, progressed after platinum, not candidates for surgery/radiation II/0109, EC decision 25/04/2022. EU has no tumour-agnostic MSI-H indication. Source
Keytruda, Keytruda Qlex 		MSI-H / dMMR endometrial Approved 2022 Approved 2022

KEYNOTE-158 single-arm, 90 patients
Response 46% (35-56)Lasting 68% of responses lasted 12 months or more

Trial details and side effects
Patients
MSI-H or dMMR advanced endometrial carcinoma after prior systemic therapy (NCT02628067)
Most common side effects
fatigue, musculoskeletal pain, rash, diarrhoea, pyrexia, cough, decreased appetite
Notes
From the FDA approval notice (2022).
Source
FDA approval summary
pembrolizumab
EU (EMA), 2022
unresectable or metastatic MSI-H or dMMR, progressed after >=1 prior therapy II/0109, EC decision 25/04/2022. EU has no tumour-agnostic MSI-H indication. Source
Keytruda 		MSI-H / dMMR gastric; small intestine; biliary Not approved Approved 2022

KEYNOTE-016, -164, -012, -028 and -158 (pooled) single-arm, 149 patients
Response 40%Lasting 78% of responses lasted 6 months or more

Trial details and side effects
Patients
MSI-H or dMMR solid tumours after prior treatment (15 cancer types) (NCT02628067)
Later trial
By tumour type: colorectal 36%, other cancers 46%.
Notes
EU indication for gastric, small intestine and biliary cancers; figures are the US pooled tumour-agnostic results.
Source
EU approval report EU figures to verify
pembrolizumab
FDA, 2017
unresectable or metastatic MSI-H or dMMR, progressed after prior treatment AA 23/05/2017, converted to regular approval 28/03/2023. Current label: MSI-H/dMMR solid tumours progressed after prior treatment, adults and children (CRC is now a separate indication). Source
FDA, 2025
unresectable or metastatic MSI-H or dMMR, progressed after prior treatment, no satisfactory alternatives, age >=12 Subcutaneous pembrolizumab approved 19/09/2025 for IV Keytruda solid-tumour indications (adults and >=12 years); label 1.6. Source
Keytruda, Keytruda Qlex 		MSI-H / dMMR solid tumours (tumour-agnostic) Approved 2017 Not approved

KEYNOTE-016, -164, -012, -028 and -158 (pooled) single-arm, 149 patients
Response 40%Lasting 78% of responses lasted 6 months or more

Trial details and side effects
Patients
MSI-H or dMMR solid tumours after prior treatment (15 cancer types) (NCT02628067)
Later trial
By tumour type: colorectal 36%, other cancers 46%.
Notes
First tumour-agnostic approval (2017). From the FDA approval report.
Source
US approval report

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 40 75 Phase 3
KRAS G12C 33 43 Phase 3
KRAS G12D 16 24 Phase 3
BRAF V600E 14 34 Phase 4
BRCA1/2 mutation 7 9 Phase 3
EGFR exon 19 deletion / L858R 7 26 Phase 3
HER2 (ERBB2) activating mutation 7 7 Phase 3
ALK fusion 6 17 Phase 3
Claudin 18.2 expression 5 5 Phase 3
IDH1/2 mutation 3 3 Phase 2
RET fusion or mutation 3 5 Phase 4
FGFR3 alteration (mutation or fusion) 2 5 Phase 3
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 2 3 Phase 2
NTRK1/2/3 fusion 2 2 Phase 4
FGFR2 fusion or rearrangement 1 3 Phase 3
PIK3CA activating mutation 1 1 Phase 1/2
ROS1 fusion 1 5 Phase 3
MET exon 14 skipping 0 2 –
NPM1 mutation 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of pembrolizumab.

  1. MSD (Merck & Co.) 13
  2. Bristol Myers Squibb 6
  3. Eli Lilly 6
  4. Amgen 4
  5. Astellas 4
  6. Bayer 4
  7. Roche 3
  8. AstraZeneca 3
  9. Pfizer 3
  10. Boehringer Ingelheim 3
  11. Revolution Medicines 2
  12. BridgeBio Oncology Therapeutics 2

Trials

126 of 218 trials shown

  1. Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

    Not yet recruiting Phase 4 Fujian Medical University Started 2025Primary completion 2027-12 NCT07010393

    dabrafenib FDA EUtrametinib FDA EUselpercatinibpralsetiniblenvatiniblarotrectinibanlotinibpembrolizumabsintilimabcabozantinibBemosuzumab

    BRAF V600E mutation

    BRAF V600ERET fusion or mutationNTRK1/2/3 fusionThyroid Neoplasms

  2. Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

    Not yet recruiting Phase 3 Transcenta Therapeutics Starts 2027Primary completion 2029-10 NCT06093425

    pembrolizumaboxaliplatinleucovorinfluorouracil

    Positive CLDN18.2 expression in tumor tissue confirmed by the central laboratory at screening using CTA (Cl…

    Claudin 18.2 expressionGastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer

  3. A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting Phase 3 Roche Started 2026Primary completion 2032-01 NCT07541170

    divarasibpembrolizumabnivolumab

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CNon-small Cell Lung Cancer

  4. MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

    Recruiting Phase 3 MSD (Merck & Co.) Started 2026Primary completion 2039-10 NCT07431827

    calderasibpembrolizumab

    Tumor tissue shows the presence of Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation

    KRAS G12CNon-small Cell Lung Cancer

  5. Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

    Recruiting Phase 3 Revolution Medicines Started 2026Primary completion 2029-10 NCT07777822

    zoldonrasibpembrolizumabpemetrexedcisplatincarboplatin

    …herapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

    KRAS G12DNSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer

  6. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    Recruiting Phase 3 Boehringer Ingelheim Started 2026Primary completion 2032-02 NCT07195695

    zongertinib FDApembrolizumabatezolizumabdurvalumabnivolumab

    HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor recepto…

    HER2 (ERBB2) activating mutationNon-small Cell Lung Cancer

  7. A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

    Recruiting Phase 3 GSK Started 2026Primary completion 2030-07 NCT07286266

    Mocertatug rezetecanpaclitaxelpegylated liposomal doxorubicintopotecangemcitabinepembrolizumabbevacizumab FDA EU

    PARPi, in participants with known or suspected deleterious germline or somatic BRCA mutations and who achieved a complete or partial response to platinum-based chemotherapy must have …

    BRCA1/2 mutationOvarian Neoplasms

  8. A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation

    Recruiting Phase 3 EuroCityClinic Started 2026Primary completion 2028-08 NCT07809256

    lenvatinibpembrolizumab

    Have a confirmed RET gene rearrangement, identified using a validated molecular test, such as next-generation sequencing (NGS), p…

    RET fusion or mutationNSCLC (Non-small Cell Lung Cancer)R

  9. A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

    Recruiting Phase 3 Astellas Started 2026Primary completion 2031-02 NCT07673887

    ASP2138pembrolizumaboxaliplatincapecitabineleucovorinfluorouracil

    Participant has CLDN18.2-positive tumor as determined by central testing.

    Claudin 18.2 expressionGastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma

  10. A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

    Recruiting Phase 3 MSD (Merck & Co.) Started 2025Primary completion 2029-12 NCT07190248

    calderasibpembrolizumabpemetrexedcisplatincarboplatin

    …inum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

    KRAS G12CNon-small Cell Lung Cancer

  11. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    Recruiting Phase 3 Bristol Myers Squibb Started 2025Primary completion 2029-09 NCT06875310

    adagrasib FDA EUpembrolizumabcarboplatinpemetrexedcisplatin

    …istologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA).

    KRAS G12CCarcinoma, Non-Small-Cell Lung

  12. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 3 Roche Started 2025Primary completion 2028-11 NCT06793215

    divarasibpembrolizumabpemetrexedcarboplatincisplatin

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CNon-Small Cell Lung Cancer, KRAS G12C Lung Cancer

  13. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    Recruiting Phase 3 Eli Lilly Started 2025Primary completion 2029-05 NCT06890598

    olomorasibpembrolizumabdurvalumab

    Must have disease with evidence of KRAS G12C mutation.

    KRAS G12CCarcinoma, Non-Small-Cell Lung

  14. A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

    Recruiting Phase 3 Baili-Bio / SystImmune Started 2025Primary completion 2027-12 NCT07178795

    BL-M07D1pembrolizumabpemetrexedcarboplatincisplatin

    A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

    HER2 (ERBB2) activating mutationNon-squamous Non-small Cell Lung Cancer

  15. A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

    Not yet recruiting Phase 3 Henlius Started 2025Primary completion 2027-04 NCT06847334

    HLX17pembrolizumab

    Without any tumor activating EGFR mutation or ALK or ROS1 gene rearrangement.

    ROS1 fusionNon-Squamous Non-Small Cell Lung Cancer

  16. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

    Recruiting Phase 3 Astellas Started 2025Primary completion 2028-09 NCT06901531

    zolbetuximab FDA EUpembrolizumabcapecitabineoxaliplatinleucovorinfluorouracil

    Participant's tumor expresses Claudin18.2 (CLDN18.2) in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining a…

    Claudin 18.2 expressionLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

  17. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    Recruiting Phase 3 MSD (Merck & Co.) Started 2024Primary completion 2028-01 NCT06345729

    calderasibpembrolizumab

    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tum…

    KRAS G12CNon-small Cell Lung Cancer

  18. VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

    Recruiting Phase 3 Replimune Started 2024Primary completion 2030-09 NCT06264180

    Vusolimogene OderparepvecnivolumabrelatlimabpembrolizumabSingle-agent chemotherapy

    …apy must be the immediate prior line of treatment before randomization (for patients with BRAF mutation, see I 4).

    BRAF V600EAdvanced Melanoma

  19. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    Recruiting Phase 3 Bayer Started 2024Primary completion 2027-10 NCT06452277

    sevabertinib FDApembrolizumabcisplatincarboplatinpemetrexed

    Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified…

    HER2 (ERBB2) activating mutationAdvanced Non-small Cell Lung Cancer, HER2 Mutation

  20. Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

    Active, not recruiting Phase 3 Boehringer Ingelheim Started 2024Primary completion 2026-12 NCT06151574

    zongertinib FDApembrolizumabcisplatincarboplatinpemetrexed

    Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.

    HER2 (ERBB2) activating mutationLung Cancer, Non-squamous, Non-small Cell

  21. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    Recruiting Phase 3 Eli Lilly Started 2023Primary completion 2027-11 NCT06119581

    olomorasibpembrolizumabcisplatincarboplatinpemetrexed

    Must have disease with evidence of KRAS G12C mutation.

    KRAS G12CCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

  22. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    Recruiting Phase 3 Amgen Started 2023Primary completion 2027-06 NCT05920356

    sotorasib FDA EUpembrolizumab

    G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing…

    KRAS G12CNon-Small Cell Lung Cancer (NSCLC)

  23. Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

    Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2022Primary completion 2028-09 NCT05239741

    pembrolizumab FDA EUoxaliplatinleucovorinfluorouracilirinotecanbevacizumabcetuximab

    …ersus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)

    MSI-H / dMMRColorectal Neoplasms

  24. Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

    Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2022Primary completion 2027-05 NCT05173987

    pembrolizumab FDA EUcarboplatinpaclitaxeldocetaxelcisplatin

    …l Carcinoma (EC) or carcinosarcoma (mixed Mullerian tumor) that is centrally confirmed as dMMR.

    MSI-H / dMMREndometrial Neoplasms

  25. A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

    Active, not recruiting Phase 3 Pfizer Started 2021Primary completion 2026-10 NCT04657991

    encorafenib FDA EUbinimetinib FDA EUpembrolizumab

    Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-…

    BRAF V600EMelanoma

  26. A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

    Active, not recruiting Phase 3 AstraZeneca Started 2021Primary completion 2026-06 NCT05048797

    trastuzumab deruxtecan FDA EUcisplatincarboplatinpembrolizumabpemetrexed

    Histologically documented non-squamous NSCLC with HER2 mutation in exons 19 or 20 by tissue NGS or ctDNA

    HER2 (ERBB2) activating mutationLocally Advanced or Metastatic Non-Small Cell Lung Cancer

  27. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    Recruiting Phase 2/3 Bristol Myers Squibb Started 2020Primary completion 2028-10 NCT04613596

    adagrasib FDA EUpembrolizumab

    Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS

    KRAS G12CAdvanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

  28. A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    Active, not recruiting Phase 3 Eli Lilly Started 2020Primary completion 2023-05 NCT04194944

    selpercatinib FDA EUcarboplatincisplatinpemetrexedpembrolizumab

    A RET gene fusion in tumor and/or blood from a qualified laboratory.

    RET fusion or mutationNon-Small Cell Lung Cancer

  29. Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

    Active, not recruiting Phase 3 National Cancer Institute (NCI) Started 2020Primary completion 2025-12 NCT04214067

    pembrolizumab FDA EU

    Patients must have deficient mismatch repair as demonstrated by lack of expression of at least one mismatch repair protein by immunohi…

    MSI-H / dMMREndometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

  30. PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

    Active, not recruiting Phase 3 UNICANCER Started 2018Primary completion 2026-12 NCT03774732

    pembrolizumabcarboplatinpaclitaxelnab-paclitaxelcisplatinpemetrexed

    Non-squamous NSCLC with targetable tumor mutations, activating EGFR mutations or ALK translocation Note: documentation of these mutation for non-squamous histology is …

    EGFR exon 19 deletion / L858RALK fusionNon Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4

  31. A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

    Active, not recruiting Phase 3 Johnson & Johnson Started 2018Primary completion 2024-04 NCT03390504

    erdafitinib FDA EUVinfluninedocetaxelpembrolizumab

    …ticipants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

    FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementUrothelial Cancer

  32. Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

    Not yet recruiting Phase 2 Washington University School of Medicine Started 2026Primary completion 2029-04 NCT07886905

    dabrafenib FDA EUtrametinib FDA EUpembrolizumab

    BRAF-V600E positive by IHC.

    BRAF V600EAnaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma

  33. Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    Recruiting Phase 1/2 Aminex Therapeutics Started 2026Primary completion 2028-02 NCT07287917

    AMXT 1501 DicaprateDFMOfulvestrant FDA EUcapivasertib FDA EUpembrolizumab

    …cancer patients: locally advanced or metastatic breast cancer with one or more actionable PIK3CA/AKT1/PTEN-alterations following progression on at least 2 endocrine-based regimens in the metastatic setting or…

    PIK3CA activating mutationMelanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer

  34. Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

    Recruiting Phase 2 Boehringer Ingelheim Started 2026Primary completion 2027-08 NCT07486817

    zongertinib FDAcisplatincarboplatinpemetrexedpembrolizumab

    Documented activating human epidermal growth factor receptor 2 (HER2) mutation as per existing local lab result

    HER2 (ERBB2) activating mutationLung Cancer, Non-squamous, Non-small Cell

  35. GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

    Recruiting Phase 2 Mayo Clinic Started 2026Primary completion 2029-09 NCT07301268

    Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102pembrolizumab

    and IDH mutated WHO grade 4 astrocytoma

    IDH1/2 mutationGlioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma

  36. A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Recruiting Phase 1/2 Antengene Biologics Started 2026Primary completion 2027-09 NCT07327229

    ATG-022pembrolizumabCAPOX

    …tological confirmation of gastric cancer or gastroesophageal junction adenocarcinoma with CLDN 18.2 positive, HER2-negative and PD-L1 positive expression.

    Claudin 18.2 expressionUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  37. Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

    Not yet recruiting Phase 2 Ismail Gögenur Started 2026Primary completion 2028-03 NCT07409844

    pembrolizumab FDA EU

    Clinical UICC stage I-III dMMR colon carcinoma

    MSI-H / dMMRDMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III, Pembrolizumab

  38. A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

    Recruiting Phase 2 Bayer Started 2026Primary completion 2028-06 NCT07811193

    VVD-133214pembrolizumab FDA EU

    Have a known microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) tumor status confirmed per local standard o…

    MSI-H / dMMRColorectal Adenocarcinoma

  39. A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

    Recruiting Phase 1/2 MSD (Merck & Co.) Started 2026Primary completion 2029-03 NCT07302347

    pembrolizumab FDA EU

    For participants with microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) solid tumors:

    MSI-H / dMMRMalignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma

  40. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

    Recruiting Phase 1/2 Eikon Therapeutics Started 2026Primary completion 2029-03 NCT07262619

    EIK1005pembrolizumab FDA EU

    Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor.

    MSI-H / dMMRAdvanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer

  41. Clinical Trial of TB511 in Advanced Solid Tumors

    Not yet recruiting Phase 1/2 Twinpig Biolab Started 2026Primary completion 2027-03 NCT06400160

    TB511pembrolizumab FDA EU

    …hageal cancer, renal cell carcinoma, endometrial cancer, microsatellite instability-high (MSI-H) cancer, MSI-H colorectal cancer, triple-negative breast cancer, cervical cancer, biliary…

    MSI-H / dMMRNSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma

  42. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

    Recruiting Phase 1/2 Bristol Myers Squibb Started 2025Primary completion 2031-02 NCT06618287

    izalontamab brengitecanosimertinib FDA EUpembrolizumabnivolumabpumitamig

    …ants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, w…

    EGFR exon 19 deletion / L858RLung Cancer, Breast Cancer

  43. KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

    Recruiting Phase 2 MSD (Merck & Co.) Started 2025Primary completion 2029-11 NCT07252739

    calderasibpembrolizumabcetuximabsacituzumab tirumotecanRescue medication

    …cid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations

    KRAS G12CMalignant Neoplasm

  44. A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

    Recruiting Phase 1/2 Bristol Myers Squibb Started 2025Primary completion 2028-10 NCT07223047

    BMS-986523gemcitabinenab-paclitaxelcetuximabpembrolizumab

    …etastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).

    KRAS G12CKRAS G12DAdvanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

  45. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    Recruiting Phase 1/2 Verastem Started 2025Primary completion 2028-12 NCT07020221

    VS-7375cetuximabcarboplatinpemetrexedpembrolizumabgemcitabinenab-paclitaxeldefactinibmidazolamRepaglinide

    …cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation.

    KRAS G12DPancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult

  46. PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

    Active, not recruiting Phase 2 Grupo Español Multidisciplinar de Melanoma Started 2025Primary completion 2027-06 NCT06906822

    enfortumab vedotinpembrolizumab

    BRAF mutated patients should have received BRAF/MEK inhibitors and PD1/PDL1 therapy c.

    BRAF V600EMelanoma

  47. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    Recruiting Phase 2 Diwakar Davar Started 2025Primary completion 2030-11 NCT07223424

    nivolumab FDA EUpembrolizumab FDA EU

    …lumab is FDA-approved in the following indications: RCC, melanoma, NSCLC, SCCHN, UC, dMMR/MSI-H CRC, HCC, esophageal cancer, and gastric, gastroesophageal and esophageal adenocarcinoma …

    MSI-H / dMMRRenal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC)

  48. Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.

    Not yet recruiting Phase 2 GERCOR - Multidisciplinary Oncology Cooperative Group Started 2025Primary completion 2027-12 NCT06646445

    pembrolizumab FDA EUAdjuvant chemotherapy

    Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.

    MSI-H / dMMRColon Cancer

  49. Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

    Recruiting Phase 2 Cambridge University Hospitals NHS Foundation Trust Started 2025Primary completion 2027-07 NCT05093231

    pembrolizumab FDA EUolaparib

    Confirmation that the PDA has TMB \>4 mutations/Mb, or dMMR gene mutation, or MSI-H by IHC.

    MSI-H / dMMRPancreatic Cancer

  50. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    Recruiting Phase 1/2 Revolution Medicines Started 2024Primary completion 2027-06 NCT06162221

    elironrasibdaraxonrasibpembrolizumabcisplatincarboplatinpemetrexedzoldonrasib

    Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)

    KRAS G12CKRAS G12DNon-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

  51. A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

    Active, not recruiting Phase 2 AstraZeneca Started 2024Primary completion 2026-10 NCT06008093

    durvalumabtremelimumabpemetrexedpembrolizumabcarboplatincisplatin

    Participants must have tumors with STK11 or KEAP1 or KRAS mutations.

    KRAS G12CKRAS G12DCarcinoma, Non-Small-Cell Lung

  52. Pembrolizumab in High-risk Thyroid Cancer

    Recruiting Phase 2 Istituti Clinici Scientifici Maugeri SpA Started 2024Primary completion 2026-11 NCT05852223

    pembrolizumab

    multifocal papillary microcarcinoma with extra tumor extension (ETE) and known BRAF V600E mutation

    BRAF V600EDifferentiated Thyroid Cancer

  53. Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

    Recruiting Phase 2 Okayama University Started 2024Primary completion 2028-06 NCT05485766

    pembrolizumabpaclitaxelcarboplatinolaparib FDA EU

    Confirmed germline BRCA 1/2 mutated.

    BRCA1/2 mutationTriple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer

  54. Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

    Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2026-11 NCT05266846

    pembrolizumabpemetrexedbevacizumabcisplatin

    Stage IV ALK-rearranged Lung Adenocarcinoma Persistent with 5'ALK Failed from first line Alectinib

    ALK fusionStatus may be outdated, last updated 2024-05-30ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy

  55. Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer

    Active, not recruiting Phase 2 Blokhin's Russian Cancer Research Center Started 2024Primary completion 2025-12 NCT07523763

    nivolumab FDA EUpembrolizumab FDA EU

    Presence of MSI/dMMR in the tumor;

    MSI-H / dMMRColorectal Cancer (MSI-H), Colorectal Cancer (CRC)

  56. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

    Active, not recruiting Phase 1/2 Servier Bio-Innovation Started 2024Primary completion 2027-08 NCT06116136

    S095029pembrolizumab FDA EU

    … Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer

    MSI-H / dMMRMSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

  57. A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

    Active, not recruiting Phase 2 Klus Pharma Started 2023Primary completion 2026-06 NCT05816252

    sacituzumab tirumotecanpembrolizumabcarboplatinosimertinib FDA EU

    or confirmed to harbor EGFR mutation;

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  58. A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

    Recruiting Phase 1/2 Roche Started 2023Primary completion 2032-01 NCT05789082

    divarasibpembrolizumabcarboplatincisplatinpemetrexed

    …ipants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

    KRAS G12CNon-Small Cell Lung Cancer

  59. Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

    Recruiting Phase 1/2 Maastricht University Medical Center Started 2023Primary completion 2027-02 NCT04954599

    CP-506carboplatinipilimumabnivolumabpembrolizumabatezolizumabavelumabdurvalumabcemiplimab

    BRCA1/2 carriers), dedicated HRD genomic assays (including exome-sequencing) from liquid or tissue biopsie…

    BRCA1/2 mutationUnspecified Adult Solid Tumor, Protocol Specific

  60. Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer

    Active, not recruiting Phase 2 University Medical Center Groningen Started 2023Primary completion 2027-12 NCT06180733

    pembrolizumab FDA EU

    … day of signing informed consent with histologically confirmed primary diagnosis of G3/CC MMRd uterine cancer who are intended to be treated with hysterectomy.

    MSI-H / dMMREndometrial Cancer

  61. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    Recruiting Phase 1/2 Genmab Started 2022Primary completion 2027-07 NCT05579366

    rinatabart sesutecancarboplatinbevacizumabpembrolizumaberythromycinitraconazole

    …ncer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negati…

    EGFR exon 19 deletion / L858RBRCA1/2 mutationHigh Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

  62. A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

    Recruiting Phase 1/2 D3 Bio Started 2022Primary completion 2027-04 NCT05410145

    D3S-001pembrolizumabcisplatincarboplatinpemetrexedcetuximab

    Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.

    KRAS G12CKRAS P.G12C

  63. Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

    Active, not recruiting Phase 2 Bristol Myers Squibb Started 2022Primary completion 2026-09 NCT05609578

    adagrasib FDA EUpembrolizumabpemetrexedcisplatincarboplatin

    … unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutation and histologically confirmed PD-L1 TPS ≥1%.

    KRAS G12CAdvanced NSCLC, Metastatic Lung Cancer

  64. A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 Immuneering Started 2022Primary completion 2027-06 NCT05585320

    atebimetinibgemcitabinenab-paclitaxelFOLFIRINOXdabrafenibpembrolizumab

    …sectable or metastatic solid tumor malignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non-small cell lung cancer (NSCLC)

    KRAS G12CKRAS G12DBRAF V600EAdvanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)

  65. A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

    Active, not recruiting Phase 2 Pfizer Started 2022Primary completion 2026-06 NCT05217446

    encorafenib FDA EUcetuximab FDA EUpembrolizumab

    Locally confirmed BRAF V600E mutation in tumor tissue or blood

    BRAF V600EMSI-H / dMMRMetastatic Colorectal Cancer

  66. Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

    Active, not recruiting Phase 2 UNICANCER Started 2022Primary completion 2026-05 NCT04074096

    binimetinib FDA EUencorafenib FDA EUpembrolizumab

    Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

    BRAF V600EMalignant Melanoma, BRAF V600 Mutation, Brain Metastases

  67. A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

    Active, not recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2022Primary completion 2025-05 NCT05203445

    olaparib FDA EUpembrolizumab

    All patients must have a germline mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.

    BRCA1/2 mutationBreast Cancer

  68. Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2022Primary completion 2027-01 NCT05188508

    pembrolizumabolaparibtemozolomide

    Histologically confirmed grade II or III IDH-mutated glioma (absence of known CDKN2A/B deletion) that has recurred after first line therapy (c…

    IDH1/2 mutationGlioma

  69. Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

    Active, not recruiting Phase 2 The Netherlands Cancer Institute Started 2022Primary completion 2030-07 NCT05131919

    pembrolizumab FDA EU

    Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

    MSI-H / dMMRColorectal Cancer

  70. NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

    Active, not recruiting Phase 2 University College, London Started 2022Primary completion 2029-11 NCT05197322

    pembrolizumab FDA EU

    Histologically proven adenocarcinoma of the colon or rectum which is MMR-d by IHC or MSI-H by PCR (or microsatellite testing if routine practice).

    MSI-H / dMMRAdenocarcinoma of the Colon

  71. T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 Alexander B Olawaiye, MD Started 2022Primary completion 2030-05 NCT05200559

    pembrolizumab FDA EUE7777

    …ma, non-small cell lung cancer, renal cell carcinoma, endometrial cancer, ovarian cancer, MSI-H solid tumors (deficient mismatch repair system or other solid tumors) that have progresse…

    MSI-H / dMMREpithelial Ovarian Cancer

  72. A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

    Active, not recruiting Phase 2 Shanghai Chest Hospital Started 2021Primary completion 2025-12 NCT05078931

    pembrolizumablenvatinib

    Have confirmation with sensitizing EGFR mutations, either DEL19 or L858R

    EGFR exon 19 deletion / L858RNSCLC

  73. Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

    Active, not recruiting Phase 1/2 Eli Lilly Started 2021Primary completion 2027-04 NCT04956640

    olomorasibpembrolizumabcetuximabpemetrexedcisplatincarboplatin

    Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).

    KRAS G12CCarcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

  74. Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2021Primary completion 2028-10 NCT04675710

    dabrafenib FDA EUpembrolizumabtrametinib FDA EU

    Must have a BRAFV600E mutation-positive tumor, as determined by BRAF V600E immunohistochemistry on tumor tissue…

    BRAF V600EThyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma

  75. Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2021Primary completion 2025-07 NCT04548752

    olaparib FDA EUpembrolizumab

    Patients must have one of the following mutations: germline mutation in BRCA 1 or 2 that was tested in a Clinical Laboratory Improvement Act (CLIA) certified lab defi…

    BRCA1/2 mutationMetastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

  76. RAPA-201 Therapy of Solid Tumors

    Recruiting Phase 1/2 Rapa Therapeutics Started 2021Primary completion 2026-01 NCT05144698

    RAPA-201pembrolizumab

    …c alterations and mutations (including but not limited to BRAF, BRCA, EGFR mutations, and ALK translocations) must have either received targeted therapy for such conditions or provided written docum…

    ALK fusionSolid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity

  77. Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2021Primary completion 2027-03 NCT04976634

    pembrolizumab FDA EUBelzutifanlenvatinib

    Colorectal cancer (CRC) (non-microsatellite instability-high \[non-MSI-H\]/deficient mismatch repair \[dMMR\])

    MSI-H / dMMRNeoplasm Malignant

  78. Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2021Primary completion 2025-05 NCT04895722

    pembrolizumab FDA EUMK-4830

    Has locally confirmed dMMR/MSI-H

    MSI-H / dMMRColorectal Cancer

  79. Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2021Primary completion 2027-12 NCT04729322

    Fecal Microbiota Transplantation CapsuleMetronidazoleNeomycinnivolumab FDA EUpembrolizumab FDA EUVancomycin

    Tumor that is deficient in mismatch repair (dMMR) or microsatellite instability high (MSI-H) as determined by one of three methods:

    MSI-H / dMMRMetastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8

  80. Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.

    Active, not recruiting Phase 2 Centre Leon Berard Started 2021Primary completion 2023-10 NCT04795661

    pembrolizumab FDA EU

    MSI/dMMR established by immunohistochemistry (IHC) \[MMR protein expression\] and polymerase chain…

    MSI-H / dMMRLocalized Resectable Tumor, MSI/dMMR

  81. Study to Evaluate D-1553 in Subjects With Solid Tumors

    Active, not recruiting Phase 1/2 InventisBio Started 2020Primary completion 2024-04 NCT04585035

    garsorasibpembrolizumabcetuximab

    Subject has KRasG12C mutation in tumor tissue or other bio-specimens containing cancer cells or DNA.

    KRAS G12CSolid Tumor, Adult, NSCLC, CRC

  82. Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

    Active, not recruiting Phase 2 AstraZeneca Started 2020Primary completion 2027-05 NCT04379596

    fluorouracilcapecitabinedurvalumaboxaliplatintrastuzumabtrastuzumab deruxtecan FDA EUcisplatinpembrolizumabVolrustomigRilvegostomig

    … 3b,4b and Part 5, pathologically documented adenocarcinoma of the stomach/GEJ/esophagus, HER2-low (IHC 2+/ISH-negative or IHC 1+) based on local tissue testing results

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Gastric Cancer

  83. A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

    Active, not recruiting Phase 2 VA Office of Research and Development Started 2020Primary completion 2026-02 NCT04104893

    pembrolizumab FDA EU

    dMMR or CDK12-/- as determined by somatic tumor DNA NGS.

    MSI-H / dMMRMetastatic Castration Resistant Prostate Cancer

  84. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

    Recruiting Phase 2 Dan Zandberg Started 2020Primary completion 2032-04 NCT04114136

    nivolumab FDA EUpembrolizumab FDA EUmetforminRosiglitazone

    … confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which c…

    MSI-H / dMMRMelanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer

  85. Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

    Active, not recruiting Phase 1/2 Bristol Myers Squibb Started 2019Primary completion 2026-06 NCT03785249

    adagrasib FDA EUpembrolizumabcetuximabafatinib

    Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation

    KRAS G12CAdvanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease

  86. Study of NEO-201 in Solid Tumors Expansion Cohorts

    Active, not recruiting Phase 1/2 Precision Biologics Started 2019Primary completion 2026-06 NCT03476681

    pembrolizumab

    Patients with EGFR, ALK1, ROS1 or BRAF V600E genomic tumor aberrations must have had disease progression on FDA-approved agents for th…

    BRAF V600EMSI-H / dMMRNon Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer

  87. Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

    Active, not recruiting Phase 1/2 City of Hope Medical Center Started 2019Primary completion 2023-05 NCT03598998

    pembrolizumabPralatrexate

    Anaplastic large cell lymphoma, ALK-positive

    ALK fusionAnaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma

  88. Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

    Active, not recruiting Phase 1/2 Nouscom Started 2019Primary completion 2026-10 NCT04041310

    GAd-209-FSP low doseMVA-209GAd-209-FSP high doseGAd20-209-FSP, RP2Dpembrolizumab FDA EU

    Have previously proven microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status (confirmatory testing is not required)…

    MSI-H / dMMRSolid Tumor, Adult

  89. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    Recruiting Phase 1/2 Inhibrx Biosciences Started 2019Primary completion 2033-07 NCT04198766

    INBRX-106 - Hexavalent OX40 agonist antibodypembrolizumab FDA EUcarboplatinpemetrexedcisplatinpaclitaxelnab-paclitaxelgemcitabine

    …hout chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metas…

    MSI-H / dMMRSolid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma

  90. Melanoma Metastasized to the Brain and Steroids

    Recruiting Phase 2 Inge Marie Svane Started 2018Primary completion 2024-06 NCT03563729

    pembrolizumabipilimumabnivolumabencorafenib FDA EUbinimetinib FDA EUdabrafenib FDA EUtrametinib FDA EU

    For arm E specifically: Tumor cells must harbor BRAF mutation.

    BRAF V600EStatus may be outdated, last updated 2023-07-13Malignant Melanoma

  91. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    Recruiting Phase 1/2 VM Oncology Started 2018Primary completion 2027-12 NCT03556228

    VMD-928 100 mg Tabletpembrolizumab

    (B) any NTRK1 gene fusion positive ("NTRK1+") solid tumors or lymphomas, that is relapsed, refractory or intolerant…

    NTRK1/2/3 fusionHead and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer

  92. A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

    Active, not recruiting Phase 2 Astellas Started 2018Primary completion 2027-06 NCT03505320

    zolbetuximab FDA EUoxaliplatinleucovorinfluorouracilpembrolizumabnivolumabdocetaxel

    Subject's tumor is positive for CLDN18.2 expression demonstrating moderate to strong membranous staining as determined by central …

    Claudin 18.2 expressionPharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin

  93. Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

    Active, not recruiting Phase 2 IMV Started 2018Primary completion 2023-12 NCT03836352

    cyclophosphamidepembrolizumab FDA EU

    Microsatellite instability high solid tumours, other than the above indications

    MSI-H / dMMRStatus may be outdated, last updated 2022-03-31Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer

  94. Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

    Active, not recruiting Phase 2 Melanoma Institute Australia Started 2017Primary completion 2022-01 NCT02858921

    dabrafenib FDA EUtrametinib FDA EUpembrolizumab

    A positive V600E immunohistochemistry stain at study entry should be formally quantified with a local mole…

    BRAF V600EMelanoma

  95. Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

    Active, not recruiting Phase 2 Rutgers, The State University of New Jersey Started 2017Primary completion 2026-08 NCT03257163

    capecitabinepembrolizumab FDA EU

    Mismatch repair deficiency as identified by immunohistochemistry or other institutional standard, or Epstein-Barr vi…

    MSI-H / dMMREpstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency, Stage IB Gastric Cancer AJCC v7

  96. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2015Primary completion 2027-05 NCT02628067

    pembrolizumab FDA EU

    …r, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H) OR

    MSI-H / dMMRAdvanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer

  97. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    Recruiting Phase 1 Kestrel Therapeutics Started 2026Primary completion 2028-04 NCT07458347

    KST-6051gemcitabinenab-paclitaxelcetuximabpembrolizumabmFOLFOX6FOLFIRIpemetrexedcarboplatin

    Documentation of KRAS mutation prior to the first dose of trial drug(s).

    KRAS G12CKRAS G12DKRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors

  98. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2025Primary completion 2027-08 NCT06917079

    BBO-11818pembrolizumabcisplatincarboplatinpemetrexedcetuximabmFOLFOX6BBO-10203mFOLFIRINOXgemcitabinenab-paclitaxel

    …ced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation

    KRAS G12CKRAS G12DNon-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)

  99. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    Recruiting Phase 1 Amgen Started 2025Primary completion 2028-04 NCT07094113

    AMG 410pembrolizumabpanitumumab FDA

    Pathologically documented, locally-advanced or metastatic malignancy with any missense mutation in the KRAS gene or evidence of KRAS amplification using an analytically validated KRASWT amplificati…

    KRAS G12CKRAS G12DKRAS Altered Advanced or Metastatic Solid Tumors

  100. A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

    Recruiting Phase 1 MSD (Merck & Co.) Started 2025Primary completion 2030-12 NCT07247110

    MK-4716pembrolizumabcetuximab

    …716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration

    KRAS G12CKRAS G12DMalignant Neoplasm

  101. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    Recruiting Phase 1 Alterome Therapeutics Started 2025Primary completion 2029-05 NCT06835569

    ALTA3263cetuximabmFOLFOX6pembrolizumabpemetrexedcisplatincarboplatinmFOLFIRINOXGnPmidazolam

    Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Impro…

    KRAS G12CKRAS G12DCancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)

  102. TLN-372 in Advanced KRAS Mutant Solid Tumors

    Recruiting Phase 1 Treeline Biosciences Started 2025Primary completion 2031-12 NCT07204340

    TLN-372cetuximabpembrolizumab

    Patients must have locally advanced or metastatic KRAS mutant solid tumors.

    KRAS G12CKRAS G12DKRAS Mutant Solid Tumors

  103. Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

    Recruiting Phase 1 Emory University Started 2025Primary completion 2026-12 NCT06324240

    ipilimumabpembrolizumabVaccine Therapy

    Patients who have a germline BRCA 1/2 mutation that meet the Food and Drug Administration (FDA) indication for use of adjuvant Olaparib …

    BRCA1/2 mutationAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8

  104. A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

    Active, not recruiting Phase 1 Eli Lilly Started 2024Primary completion 2030-01 NCT06607185

    LY4066434.cetuximabnab-paclitaxelgemcitabineoxaliplatinleucovorinirinotecanfluorouracilcarboplatincisplatinpemetrexedpembrolizumab

    Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA

    KRAS G12CKRAS G12DPancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

  105. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2031-04 NCT06343402

    BBO-8520pembrolizumabBBO-10203

    …umented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation

    KRAS G12CNon-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C

  106. Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

    Active, not recruiting Phase 1 Amgen Started 2024Primary completion 2026-10 NCT06333951

    Anvumetostatcarboplatinpaclitaxelpembrolizumabpemetrexedsotorasib FDA EU

    Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.

    KRAS G12CThoracic Tumors, Non-small Cell Lung Cancer

  107. A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

    Active, not recruiting Phase 1 Pfizer Started 2024Primary completion 2026-10 NCT06447662

    PF-07934040gemcitabinenab-paclitaxelcetuximabfluorouraciloxaliplatinleucovorinbevacizumabpembrolizumabpemetrexedcisplatinpaclitaxel

    Documentation of mutated KRAS gene

    KRAS G12DCarcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung

  108. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    Recruiting Phase 1 Bayer Started 2024Primary completion 2027-05 NCT06004245

    VVD-133214pembrolizumab FDA EUbevacizumab

    Have a microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented…

    MSI-H / dMMRAdvanced Solid Tumors, Colorectal Cancer

  109. Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

    Active, not recruiting Phase 1 MSD (Merck & Co.) Started 2023Primary completion 2028-06 NCT05853367

    MK-0472pembrolizumabcalderasib

    …histologically OR blood-based confirmation of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation

    KRAS G12CMSI-H / dMMRMetastatic Solid Tumors, Advanced Solid Tumors

  110. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

    Recruiting Phase 1 Jazz Pharmaceuticals Started 2023Primary completion 2027-11 NCT06108050

    JZP898pembrolizumab

    Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study.

    BRAF V600EMSI-H / dMMRAdvanced Solid Tumor, Metastatic Solid Tumor

  111. Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

    Active, not recruiting Phase 1 Institut de Recherches Internationales Servier Started 2023Primary completion 2026-02 NCT05484622

    vorasidenib FDA EUpembrolizumab

    Documented IDH1-R132H gene mutation

    IDH1/2 mutationAstrocytoma, Oligodendroglioma

  112. FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

    Recruiting Phase 1 Eli Lilly Started 2023Primary completion 2027-06 NCT05614739

    Vepugratinibpembrolizumabenfortumab vedotintrastuzumab deruxtecanmidazolamDigoxinRosuvastatin

    …, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy with a qualifying FGFR3 alteration.

    FGFR3 alteration (mutation or fusion)Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

  113. Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

    Active, not recruiting Phase 1 Novartis Started 2023Primary completion 2027-08 NCT05838768

    HRO761pembrolizumab FDA EUirinotecan

    Patients with advanced unresectable or metastatic MSIhi or MMR deficient (dMMR) solid tumors who have progressed after or are intolerant to prior standard therapy…

    MSI-H / dMMRMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

  114. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

    Recruiting Phase 1 Bayer Started 2023Primary completion 2030-08 NCT05954312

    VVD-130037docetaxelpaclitaxelpembrolizumab FDA EU

    …eckpoint inhibitor (for tumors with known programmed death-ligand 1 \[PD-L1\] expression, microsatellite instability-high, or mismatch repair deficiency, and an anti-epidermal growth factor receptor agent) (Comb…

    MSI-H / dMMRAdvanced Solid Tumors

  115. A Study of ASP3082 in Adults With Advanced Solid Tumors

    Recruiting Phase 1 Astellas Started 2022Primary completion 2028-12 NCT05382559

    setidegrasibcetuximableucovorinoxaliplatinfluorouracilirinotecannab-paclitaxelgemcitabinedocetaxelpembrolizumabcisplatincarboplatin

    … lung cancer (NSCLC) (Note: for Cohort H only, the tumor must be non-squamous NSCLC) with KRAS G12D mutation and

    KRAS G12DSolid Tumor

  116. A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

    Active, not recruiting Phase 1 Novartis Started 2022Primary completion 2027-10 NCT05544929

    KFA115pembrolizumab FDA EU

    …tive breast cancer, ovarian cancer (high-grade serous histology), anal cancer (squamous), MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC.

    MSI-H / dMMRCarcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial

  117. A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

    Active, not recruiting Phase 1 Cullinan Therapeutics Started 2021Primary completion 2026-03 NCT05117476

    CLN-619pembrolizumabpaclitaxelcarboplatinpemetrexeddatopotamab deruxtecan FDA

    …1: Histologically or cytologically confirmed metastatic or locally advanced, unresectable EGFRm NSCLC.

    EGFR exon 19 deletion / L858RAdvanced Solid Tumor, NSCLC

  118. A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

    Recruiting Phase 1 MSD (Merck & Co.) Started 2021Primary completion 2030-02 NCT05067283

    calderasibpembrolizumabcarboplatinpemetrexedcetuximaboxaliplatinleucovorinfluorouracil

    …e or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease

    KRAS G12CKRAS G12DAdvanced Solid Tumors

  119. DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Active, not recruiting Phase 1 Daiichi Sankyo Started 2020Primary completion 2025-07 NCT04042701

    trastuzumab deruxtecan FDA EUpembrolizumab

    Pathologically documented, locally advanced/metastatic HER2-mutant NSCLC

    HER2 (ERBB2) activating mutationHER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer, Non-small Cell Lung Carcinoma

  120. Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1 Mayo Clinic Started 2020Primary completion 2025-05 NCT04007744

    pembrolizumab FDA EUSonidegib

    Microsatellite instability-high (MSI-H) cancer.

    MSI-H / dMMRClinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8

  121. CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

    Active, not recruiting Phase 1 Jonsson Comprehensive Cancer Center Started 2019Primary completion 2026-01 NCT03546361

    Autologous Dendritic Cell-Adenovirus CCL21 Vaccinepembrolizumab

    Have received prior tyrosine kinase inhibitor therapy in patients with a sensitizing EGFR mutation and/or ALK gene rearrangement.

    EGFR exon 19 deletion / L858RALK fusionLung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

  122. Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    Active, not recruiting Phase 1 Amgen Started 2019Primary completion 2026-12 NCT04185883

    sotorasib FDA EUtrametinibvociprotafibafatinibpembrolizumabpanitumumab FDAcarboplatinpemetrexeddocetaxelpaclitaxelatezolizumabpalbociclib

    Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requireme…

    KRAS G12CAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation

  123. Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

    Active, not recruiting Phase 1 Royal Marsden NHS Foundation Trust Started 2017Primary completion 2026-09 NCT02998567

    Guadecitabinepembrolizumab FDA EUdecitabine

    Patients with microsatellite-instability-high (MSI-High) tumours, provided they have been defined by validated assays or patients with deficient …

    MSI-H / dMMRNon Small Cell Lung Cancer

  124. Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

    Active, not recruiting Early Phase 1 Memorial Sloan Kettering Cancer Center Started 2019Primary completion 2027-02 NCT03832569

    pembrolizumab FDA EU

    …tudy of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

    MSI-H / dMMRSolid Tumors, Identified by NGS, PCR or IHC

  125. PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

    Recruiting No phase Peking University People's Hospital Started 2024Primary completion 2029-07 NCT06549855

    sintilimabpembrolizumab FDA EU

    Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation se…

    MSI-H / dMMREndometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency

  126. Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

    Active, not recruiting No phase National Cancer Institute (NCI) Started 2014Primary completion 2025-12 NCT02194738

    carboplatincisplatincrizotinib FDA EUerlotinibgemcitabinenivolumabpaclitaxelpembrolizumabpemetrexed

    No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4

    ALK fusionStage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8